GSK shares positive data for Arexvy, its respiratory syncytial virus (RSV) older adult vaccine, indicating protection over two RSV seasons

New results from the ongoing AReSVi-006 phase III trial show vaccine efficacy against RSV-lower respiratory tract disease and severe disease over two full RSV seasons, including in participants with underlying medical conditions Safety and reactogenicity data were consistent with initial results from the phase III programme The clinical devel­­opment programme will continue to evaluate longer term follow up and the optimal timing for revaccination GSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating the efficacy of a single dose of Arexvy (respiratory syncytial virus vaccine, adjuvanted) against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 60 years and older over multiple RSV seasons and after annual revaccination. Efficacy of a single dose over two seasons The results show that one dose of the vaccine is efficacious against RSV-LRTD and severe LRTD over two full RSV seasons.

The release as fetched from its publisher. gsk.com ↗